Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Dermatol Ther. 2020 Mar;33(2):e13215. doi: 10.1111/dth.13215. Epub 2020 Jan 12.


Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as "vitiligo," "treatment," "recent," and "immunomodulators" to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.

Keywords: immunomodulators; new treatment; vitiligo.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunologic Factors / therapeutic use
  • PUVA Therapy
  • Prospective Studies
  • Quality of Life
  • Vitiligo* / diagnosis
  • Vitiligo* / therapy


  • Immunologic Factors